我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
32
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Biocon Limited has opened its first FDA-approved manufacturing facility in Cranbury, New Jersey, through its subsidiary Biocon Generics Inc, marking a significant milestone in the company's global expansion strategy. - The company invested over $30 million to establish the state-of-the-art oral solid dosage facility with an annual production capacity of 2 billion tablets after acquiring it from Eywa Pharma Inc. in 2023. - The facility enables Biocon to deliver vertically integrated, high-quality medicines more efficiently to US patients while strengthening supply chain resilience and accelerating global market expansion. - New Jersey Governor Phil Murphy attended the inauguration, highlighting the facility's role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem.
